A5041754259- Bone health and osteoporosis research
- Diabetes Treatment and Management
- Growth Hormone and Insulin-like Growth Factors
- Metabolism, Diabetes, and Cancer
- Electroconvulsive Therapy Studies
- Dental Implant Techniques and Outcomes
- Bipolar Disorder and Treatment
- Hypothalamic control of reproductive hormones
- Nutrition and Health in Aging
- Hip and Femur Fractures
- Lysosomal Storage Disorders Research
- Dental materials and restorations
- Body Composition Measurement Techniques
- Bone Tissue Engineering Materials
- Ovarian function and disorders
- Vitamin D Research Studies
- Child Nutrition and Feeding Issues
- Pituitary Gland Disorders and Treatments
- Stress Responses and Cortisol
- Epilepsy research and treatment
- Chronic Kidney Disease and Diabetes
- Sports Performance and Training
- Neuroblastoma Research and Treatments
- Bone health and treatments
- Glycogen Storage Diseases and Myoclonus
Centro Hospitalar do Baixo Vouga
2017-2022
Universidade Nova de Lisboa
2021
University of Lisbon
2021
Hospitais da Universidade de Coimbra
2021
University of Coimbra
2021
ORCID
2021
Institute of Integrated Clinical Research (Brazil)
2021
IPO Porto
2021
Instituto Português de Oncologia Francisco Gentil
2021
Universidade Católica de Brasília
2006-2020
Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) a meta-analysis large cardiovascular outcome trials (CVOTs) SGLT2i type diabetes mellitus.CREDENCE randomized...
Aim: The purpose of this study was to evaluate if superior glycaemic control could be achieved with Avandamet® (rosiglitazone/metformin/AVM) compared metformin (MET) monotherapy, and effects attained AVM are durable over 18 months treatment. Bone mineral density (BMD) bone biomarkers were evaluated in a subgroup patients. Methods: This phase IV, randomized, double-blind, multi-centre 688, drug naÏve, male female patients who had an established clinical diagnosis type 2 diabetes mellitus...
Abstract Purpose: The purpose of this study was to report on the outcome metal ceramic implant‐supported fixed prostheses with milled titanium frameworks and all‐ceramic crowns. Materials Methods: clinical included 108 patients (67 women, 41 men), mean age 58.6 years (range: 34–82), followed between 9 months 10 (post occlusal loading). follow‐up time for all in 5 years. A total 125 were fabricated. data divided into 2 groups. Development group (DG): 52 66 (28 maxillary, 38 mandibular)...
Human pancreatic tumor GH-releasing factor-40 (hpGRF-40) selectively stimulates GH secretion in normal men and some adults with deficiency. To study its effects women, we administered hpGRF-40 (3.33 micrograms/kg) or an equivalent volume of vehicle as iv bolus at 0900 h to 10 women during the early follicular, late midluteal phases menstrual cycle. Serum concentrations GH, PRL, LH, FSH were measured intervals between 0800-1100 h. somatomedin-C before 24 after administration hpGRF-40. Within...
In addition to stimulating GH release in normal subjects, GH-releasing hormone-40 (GHRH-40) stimulates secretion some adults and children with deficiency. Recognizing that GHRH-40 may have potential as a therapeutic agent for the treatment of deficiency, we examined effects iv, sc, intranasal (in) administration on measured plasma levels immunoreactive GHRH achieved after peptide via these different routes. Normal men were given vehicle or iv (0.003, 0.01, 0.03, 0.1 µg/kg; n = 10), sc (1,...
Human pancreatic tumor GH releasing factor-40 (hpGRF-40) selectively stimulates secretion in normal men and some adult patients with deficiency. As the latter finding suggests that children deficiency may benefit from therapy hpGRF-40 or an analogue, we investigated effect of administered intranasally on release. Six were given (30 ug/kg; test day) equivalent volume vehicle alone (control at 0900 h. Immunoreactive was measured serum obtained intervals between 0800–1200 Mean (± sem)...
In vivo studies in the human and both vitro animals have shown that GnRH-stimulated LH release is a function of gonadal steroid environment. Furthermore, when GnRH given sustained manner, pattern biphasic. Using an technique which rat anterior pituitary cells were dispersed perifusion was begun within 2 h after removal gland from donor animal, we tested hypothesis overall secretion relative sizes two phases would vary reproducible manner during estrous cycle. Sprague-Dawley rats (aged 60–70...
We have tested the influence of a new calcium ion channel antagonist, diltiazem, on hypothalamic releasing hormone-stimulated secretion LH and other anterior pituitary hormones in man. To this end, six normal men received continuous infusion GnRH (1 μg/min) TRH (2 for 3 h under three different experimental conditions: 1) saline (control) infusion; 2) iv diltiazem (0.3 mg/kg bolus dose, 0.002 mg/kg-min) 4 beginning 1 before hormone injection; 3) oral (60 mg, every 6 h) administration week...
To study in vitro the self-priming effect of GnRH on LH release, rat anterior pituitaries were prepared either as fragments or dispersed cells and continuously perifused parallel chambers. The experimental groups consisted rats killed at 0800 h diestrus day 1, 2, proestrus estrus, 1400 proestrus. insure truly independent observations, each preparation was tested three occasions. After basal release had stabilized, tissue preparations exposed to 10 nM two 30-min challenges separated by 1 h....
Abstract Aims We assessed the change from baseline in vitamin E, steroid hormones, adrenocorticotropic hormone (ACTH), and gonadotropins, overall by lowest achieved low‐density lipoprotein‐cholesterol (LDL‐C) level, patients with type 2 diabetes dyslipidaemia after 12 weeks of treatment evolocumab. Materials Methods This was a prespecified analysis cortisol, ACTH, gonadal hormones gonadotropins 12‐week, placebo‐controlled BERSON trial evolocumab dyslipidaemia. In BERSON, 981 (451 China) on...
Há um grande número de estudos mostrando que o treinamento força tem efeito positivo sobre a densidade mineral óssea (DMO). Porém, existem poucos comparando DMO entre praticantes hidroginástica e força. Objetivo: Comparar, em uma análise transversal, mulheres com hidroginástica, na pós-menopausa. A amostra foi composta 63 mulheres, divididas três grupos: (FORÇA: n = 15; 51,4 ± 2,7 anos), (HIDRO: 22; 54,5 3,3 anos) controles não treinadas (CONTROLE: 26; 52,0 anos). Todas as voluntárias...
Many studies have shown that resistance training has a positive effect on bone mineral density (BMD). However, few compared the BMD of individuals undergoing and those aquatic weight-bearing exercises. To compare, in cross-sectional study, postmenopausal women The sample comprised 63 divided into following three groups: (STRENGTH: n = 15; 51.4 ± 2.7 years); exercises (WATER: 22; 54.5 3.3 non-trained controls (CONTROL: 26; 52.0 years). All volunteers were hormone replacement therapy for at...
Evogliptin (EVO) is a potent and selective dipeptidyl peptidase-4 inhibitor (DPP4i) developed for the treatment of type 2 diabetes mellitus (T2DM). DPP4is are known to exhibit better glucose-lowering effect in Asians compared other ethnic groups. Once EVO's clinical development program was conducted Asian patients, this bridging study designed validate Brazilian population efficacy safety approved dose regimen (once-daily 5.0 mg).In randomized, double-blind, double-dummy, parallel trial, 146...